GLP-1 for PCOS in 2026: which drug, which program, and how to get coverage

TLDR.

• No GLP-1 receptor agonist is FDA-approved for PCOS as a primary indication. Eligibility runs through the obesity pathway (BMI 30+) or obesity-with-comorbidity (BMI 27+ with insulin resistance, prediabetes, or type 2 diabetes).
• GLP-1s have PCOS-specific randomized trial data, the strongest of it from liraglutide, including menstrual-cycle restoration in 50 to 70 percent of treated women over six months. Semaglutide is the same drug class.
• Tirzepatide produces more total weight loss (20.9 percent versus 14.9 percent semaglutide in registration trials) and may be superior in patients with severe insulin resistance via its dual GLP-1 and GIP mechanism.
• Cash-pay price: Mochi at $178/mo (compounded semaglutide, all doses) or $278/mo (compounded tirzepatide). Insured: PlushCare at $19.99/mo membership, medication through insurance.
• File PA under obesity (E66.9) plus insulin resistance (R73.03) plus PCOS (E28.2). Filing under E28.2 alone will be denied.
• GLP-1 must be discontinued at least two months before attempting conception. Restored ovulation can happen quickly; use effective contraception during titration if pregnancy is not the goal.

Why PCOS patients use GLP-1s

PCOS is fundamentally an insulin-resistance condition. Elevated insulin drives higher androgen production from the ovaries, which disrupts the menstrual cycle and inhibits ovulation. For women with PCOS who are also obese, the loop is self-reinforcing: excess adipose tissue drives more insulin resistance, which drives more androgen production, which makes weight loss harder.

GLP-1 receptor agonists act on three of these levers. They reduce weight (the largest body-of-evidence mechanism). They improve insulin sensitivity independent of weight loss, via both pancreatic and peripheral effects. In smaller trials, they have also shown reductions in circulating androgens (free testosterone, DHEAS) and restoration of menstrual regularity in women who were anovulatory.

For overweight PCOS patients whose insulin resistance is driving symptoms, the evidence base is genuinely strong for semaglutide and promising for tirzepatide. The drugs require a prescription and cause GI side effects during titration; whether that trade-off is right depends on the individual clinical picture.

Semaglutide vs tirzepatide: the data for PCOS specifically

No large randomized trial has compared the two drugs directly in PCOS populations. The evidence base differs substantially.

Semaglutide has the stronger PCOS-specific trial record. Frossing et al. (Diabetes, Obesity and Metabolism, 2018) randomized 49 women with PCOS and obesity to liraglutide plus metformin versus metformin alone. The GLP-1 arm produced significant improvements in menstrual regularity, androgen levels, and HOMA-IR over six months. Jensterle et al. (Endocrine Connections, 2014) showed GLP-1 superiority over sitagliptin on weight, cycle restoration, and androgen suppression. These trials used liraglutide, not semaglutide. But semaglutide is the same mechanistic class at roughly triple the GLP-1 receptor engagement per dose, so extrapolation is clinically reasonable. A 2023 systematic review (Cena et al., Reproductive Sciences) pooled eight randomized trials of GLP-1 RAs in PCOS and found consistent improvements in body weight, HOMA-IR, free testosterone, and menstrual frequency.

Tirzepatide has the stronger weight-loss record overall. SURMOUNT-1 produced 20.9 percent mean weight loss at the 15 mg dose over 72 weeks, versus 14.9 percent for semaglutide in STEP-1. For PCOS patients where weight loss is the primary lever, tirzepatide's larger reduction is a genuine argument in its favor. No PCOS-specific tirzepatide RCT has been published as of mid-2026.

Semaglutide is the better-documented choice for PCOS and cheaper at most dose tiers. Tirzepatide is the right escalation when a prescriber wants maximal weight loss or when the patient has not responded sufficiently to semaglutide. See the Wegovy vs Zepbound head-to-head for the full drug comparison.

How insurance covers GLP-1 for PCOS

PCOS is not in any major payer's PA criteria for GLP-1 drugs. Filing under E28.2 (PCOS) alone will be denied. What matters is that most PCOS patients meet one of the two coverage pathways.

Obesity indication (BMI 30+, or BMI 27+ with a qualifying comorbidity). The PA letter must establish the BMI threshold, a structured lifestyle intervention attempt (three to six months of supervised diet and exercise, documented in the chart), and failure of that intervention to produce sustained weight loss. Filing under E66.9 (obesity, unspecified) with supporting E28.2 (PCOS) and R73.03 (prediabetes or insulin resistance) gives the reviewer three converging clinical reasons to approve.

Type 2 diabetes indication. Roughly 30 to 40 percent of PCOS patients have T2D or prediabetes by the time they seek GLP-1 treatment. If HbA1c is above 5.7 percent, filing under E11.9 (T2D) with E28.2 as supporting context is often a cleaner path, because the T2D indication has broader coverage across commercial plans.

For the PA letter itself, the library at glpchart.com/pa-letter/ has templates for the PCOS plus obesity-with-comorbidity indication across all major payers. Each template includes the E66.9 plus R73.03 plus E28.2 code stack, the structured lifestyle-intervention language, and the trial-evidence citations a reviewer needs.

Which programs work for PCOS patients

Best for insured PCOS patients: PlushCare. PlushCare is a primary care telehealth practice. You see a licensed PCP who can document your PCOS diagnosis, your insulin-resistance labs, your lifestyle-intervention attempt, and write the PA letter from direct clinical knowledge. PlushCare prescribes only FDA-approved branded medications, so if your insurance covers Wegovy or Zepbound, there is no downgrade risk to compounded. Membership costs $19.99/mo after the 30-day free trial; medication runs through your pharmacy benefit.

Also strong for insured: Noom Med and Form Health. Noom Med ($279/mo membership, medication separate) handles PA for branded GLP-1s through a dedicated insurance team. Form Health ($324/mo membership, medication separate) uses board-certified obesity medicine physicians and accepts Medicare, which matters for PCOS patients who are older than is typical for the condition.

Best for cash-pay PCOS patients: Mochi. Mochi at $178/mo (compounded semaglutide, all doses) is the cheapest verified all-in cash-pay option in the chart. Membership and medication are bundled; the price does not increase as you titrate up. Compounded tirzepatide is available at $278/mo. Mochi prescribes compounded GLP-1s under active regulatory exposure from Eli Lilly litigation, and patients should understand that supply could be disrupted.

Not the right fit: programs without synchronous clinical visits. For PCOS, the PA letter requires a provider who has seen your clinical picture. An async questionnaire alone will not produce a PA letter that wins approval from Aetna or UnitedHealthcare.

The fertility consideration

GLP-1s restore ovulation in PCOS patients who have been anovulatory. The clinical trials showed 50 to 70 percent menstrual regularity restoration over six months. That benefit also means that a woman who was effectively infertile due to anovulation may become fertile while on a GLP-1, possibly before she has told her prescriber she is trying to conceive.

Both Novo Nordisk and Eli Lilly recommend discontinuing GLP-1 treatment at least two months before attempted conception, based on animal study findings at doses higher than clinical doses. There is not a large human safety database on GLP-1 exposure in the first trimester of pregnancy.

If you are sexually active and not planning pregnancy, use effective contraception during GLP-1 titration. Tell your prescriber your fertility plans before starting. If you plan to conceive within 12 months, discuss timing with your prescriber and gynecologist before starting the medication.

Cost breakdown

If your insurance covers Wegovy or Zepbound, PlushCare at $45/mo plus a $0 to $50 copay is the lowest all-in monthly cost. If you are paying cash, Mochi at $178/mo (compounded semaglutide) is the cheapest predictable all-in option in the chart.

See the full program comparison chart→

Frequently asked questions

Is GLP-1 FDA-approved for PCOS?

No. No GLP-1 receptor agonist carries an FDA indication for PCOS. All prescribing for PCOS is off-label. Insurance coverage runs through the obesity indication (BMI 30+ or 27+ with comorbidity) or the type 2 diabetes indication. File PA under those ICD-10 codes with PCOS as supporting clinical context, not as the primary indication.

Which GLP-1 is best for PCOS?

Among GLP-1s, the PCOS-specific randomized trial data is mostly from liraglutide, which is the same class as semaglutide; semaglutide is the usual starting choice. Tirzepatide produces more total weight loss and may have additional benefits via its GIP mechanism for insulin resistance, but no PCOS-specific tirzepatide RCT has been published as of mid-2026. Most prescribers start with semaglutide and escalate to tirzepatide if results are insufficient after six months.

Does PCOS help me qualify for insurance coverage?

Indirectly. PCOS paired with obesity, insulin resistance, or prediabetes creates a clinical picture that strengthens the PA. File under E66.9 (obesity) plus R73.03 (prediabetes or insulin resistance) plus E28.2 (PCOS). The E66.9 and R73.03 codes are what the insurance reviewer looks at; E28.2 provides supporting context for medical necessity.

Will GLP-1 restore my menstrual cycle?

In smaller randomized trials of GLP-1 RAs in PCOS, 50 to 70 percent of treated women had restored menstrual regularity over six months. This is not a guaranteed outcome and depends on baseline hormone levels, baseline weight, and whether insulin resistance was the primary driver of anovulation. It is an observed benefit in trial populations, not an FDA-labeled effect.

Can I get pregnant while on a GLP-1?

Novo Nordisk and Eli Lilly both recommend discontinuing GLP-1 treatment at least two months before attempting conception, based on animal study findings. Because GLP-1 can restore ovulation in anovulatory PCOS patients, use effective contraception during treatment if pregnancy is not your current goal. Tell your prescriber your fertility plans before starting the medication.

Where are the PA letter templates for PCOS?

GLP Chart publishes PA letter templates for the PCOS plus obesity-with-comorbidity indication across all major payers. Each template includes the E66.9 plus R73.03 plus E28.2 code stack, the structured lifestyle-intervention documentation prompt, and the trial-evidence citations a reviewer needs. Find them at the PA letter library.